Axon Enterprise, Inc $AXON Shares Sold by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S lessened its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 52.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,345 shares of the biotechnology company’s stock after selling 5,786 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Axon Enterprise were worth $3,036,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. NEOS Investment Management LLC boosted its holdings in shares of Axon Enterprise by 82.7% in the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock valued at $18,206,000 after buying an additional 11,482 shares in the last quarter. Legal & General Group Plc raised its position in Axon Enterprise by 1.3% in the 4th quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock valued at $242,241,000 after purchasing an additional 5,419 shares during the last quarter. Vanguard Group Inc. raised its position in Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after buying an additional 376,904 shares during the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in Axon Enterprise during the 4th quarter worth $13,116,000. Finally, Wealth Enhancement Advisory Services LLC raised its position in Axon Enterprise by 93.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 23,365 shares of the biotechnology company’s stock worth $13,270,000 after buying an additional 11,262 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insiders Place Their Bets

In other Axon Enterprise news, CRO Cameron Brooks sold 1,242 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total transaction of $621,000.00. Following the completion of the sale, the executive owned 49,710 shares in the company, valued at $24,855,000. The trade was a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick W. Smith sold 20,000 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total transaction of $10,000,000.00. Following the sale, the chief executive officer owned 3,060,997 shares of the company’s stock, valued at approximately $1,530,498,500. The trade was a 0.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 39,344 shares of company stock valued at $19,267,315. 4.20% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. The Goldman Sachs Group set a $535.00 price objective on shares of Axon Enterprise in a research report on Thursday, May 7th. TD Cowen cut their price target on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Weiss Ratings upgraded shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 8th. Needham & Company LLC dropped their target price on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a report on Friday, February 20th. Finally, Citizens Jmp decreased their price target on shares of Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating on the stock in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $712.75.

Axon Enterprise Price Performance

AXON opened at $471.06 on Tuesday. The stock has a market capitalization of $37.97 billion, a PE ratio of 189.18, a P/E/G ratio of 8.84 and a beta of 1.45. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $885.91. The company’s 50 day simple moving average is $408.45 and its 200 day simple moving average is $491.12.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. The firm had revenue of $807.35 million for the quarter, compared to analysts’ expectations of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. Axon Enterprise’s revenue was up 33.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.47 earnings per share. As a group, sell-side analysts expect that Axon Enterprise, Inc will post 1.82 EPS for the current year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.